Celesta Capital announces its investment in 1Cell.Ai, marking a strategic move to enhance India's deep tech landscape, particularly in oncology diagnostics.

Information on the Target

Celesta Capital, represented by Anita Rehman, is actively investing in the Indian deep tech sector, with a vision to drive innovation and technological advancement within the country. One such notable investment is in 1Cell.Ai, which is focused on advancing oncology through its OncoIncytes platform. This platform merges various advanced methodologies, including circulating tumor DNA (ctDNA) analysis, transcriptomics, and proteomics, to offer next-generation, AI-driven cancer diagnostics.

1Cell.Ai embodies a significant shift in the Indian healthcare landscape, taking bold steps towards offering more precise diagnostic solutions. This type of innovation demonstrates the company’s commitment to not just incremental improvements, but genuine transformational change in the medical field.

Industry Overview in India

India's deep tech landscape is experiencing rapid growth, driven by a pool of talented professionals who are harnessing their skills domestically rather than seeking opportun